NCT02864849View on ClinicalTrials.gov

Total Neoadjuvant Induction and Consolidation CapeOX Plus IMRT With Capecitabine for MRI Defined High-risk Rectal Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

June 30, 2019

Study Completion Date

June 30, 2019

Conditions

Rectal Cancer

Interventions

DRUG

Oxaliplatin

DRUG

Capecitabine

RADIATION

Intensity modulated radiotherapy

PROCEDURE

Total mesorectal excision

Trial Locations (1)

100142

Beijing Cancer Hospital, Beijing

All Listed Sponsors

lead

Peking University Cancer Hospital & Institute

OTHER

NCT02864849 - Total Neoadjuvant Induction and Consolidation CapeOX Plus IMRT With Capecitabine for MRI Defined High-risk Rectal Cancer | Biotech Hunter | Biotech Hunter